1 авг. 2022 г. · Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events.

2 янв. 2024 г. · Clopidogrel might be an attractive alternative to aspirin with a borderline ischemic benefit beyond 1 year after PCI.

Recently, we reported the 5-year results of STOPDAPT-2, which demonstrated that clopidogrel monotherapy had a marginal benefit in reducing cardiovascular events ... Abstract · Methods · Results · Discussion

The content discusses the use of antiplatelet monotherapy for secondary prevention after PCI, with aspirin being the recommended first-line agent.

Taken together, long-term clopidogrel monotherapy might be an attractive alternative to aspirin monotherapy in reducing cardiovascular events beyond 1 year ... Abstract · Methods · Results · Discussion

Clopidogrel monotherapy was noninferior, but not superior, to aspirin monotherapy for net adverse clinical events beyond 1 year after PCI by the landmark ...

3 янв. 2024 г. · Treatment with clopidogrel was associated with a significant 23% lower risk of major cardiovascular outcomes at 5 years, including a reduction ...

20 мар. 2024 г. · Clopidogrel monotherapy was associated with reduced bleeding but was not noninferior for death, myocardial infarction, or stroke. Meaning These ...

9 янв. 2023 г. · Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT reduced major bleeding events without an increase in cardiovascular events regardless of ...

7 нояб. 2022 г. · Long-term treatment with clopidogrel monotherapy leads to a consistent reduction in cardiovascular events compared with aspirin monotherapy.